A.R.T. Advisors’s Kyntra Bio KYNB Stock Holding History

A.R.T. Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,648	Closed	-$881K	–	1501
2016 Q4	$881K	Buy	+1,648	New	+$823K	0.05%	521
2016 Q3	–	Sell	-4,687	Closed	-$1.92M	–	807
2016 Q2	$1.92M	Buy	4,687 +2,521	+116%	+$1.15M	0.1%	328
2016 Q1	$1.15M	Buy	+2,166	New	+$1.08M	0.05%	526
2015 Q3	–	Sell	-827	Closed	-$485K	–	1427
2015 Q2	$485K	Buy	+827	New	+$481K	0.02%	1004

Other funds holding KYNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

A.R.T. Advisors's KYNB Position: Q1 2017 in Review

A.R.T. Advisors sold out of Kyntra Bio (KYNB) in Q1 2017, closing a stake of 1,648 shares — an estimated $881K sold.

A.R.T. Advisors first reported a position in KYNB in Q2 2015 and held it in 4 quarters. The position peaked at $1.92M in Q2 2016. 144 funds tracked by Wall St. Rank hold KYNB as of Q1 2017.

A.R.T. Advisors reported no remaining Kyntra Bio position as of Q1 2017 after selling out during the quarter.
A.R.T. Advisors sold 1,648 Kyntra Bio shares in Q1 2017, an estimated $881K.
A.R.T. Advisors first reported a position in Kyntra Bio in Q2 2015 and held it in 4 quarters.
A.R.T. Advisors's Kyntra Bio position peaked at $1.92M in Q2 2016.
144 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2017.

Based on A.R.T. Advisors's 13F filing for Q1 2017, filed 15 May 2017.